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ABSTRACT
Background. The perioperative period is important for patient outcome. Colorectal
cancer surgery can lead to metastatic disease due to release of disseminated tumor
cells and the induction of surgical stress response. To explore the overall effects on
surgically-induced changes in serum composition, in vitro model systems are useful.
Methods. A systematic search in PubMed and EMBASE was performed to identify
studies describing in vitro models used to investigate cancer cell growth/proliferation,
cell migration, cell invasion and cell death of serum taken pre- and postoperatively
from patients undergoing colorectal tumor resection.
Results. Two authors (MG and TK) independently reviewed 984 studies and identified
five studies, which fulfilled the inclusion criteria. Disagreements were solved by
discussion. All studies investigated cell proliferation and cell invasion, whereas three
studies investigated cell migration, and only one study investigated cell death/apop-
tosis. One study investigated postoperative peritoneal infection due to anastomotic
leak, one study investigated mode of anesthesia (general anesthesia with volatile or
intravenous anesthetics), and one study investigated preoperative intervention with
granulocytemacrophage colony stimulating factor (GMCSF). In all studies an increased
proliferation, cell migration and invasion was demonstrated after surgery. Anesthetics
with propofol and intervention with GMCSF significantly reduced postoperative cell
proliferation, whereas peritoneal infection enhanced the invasive capability of tumor
cells.
Conclusion. This study suggests that in vitro cell models are useful and reliable tools
to explore the effect of surgery on colorectal cancer cell proliferation and metastatic
ability. The models should therefore be considered as additional tests to investigate the
effects of perioperative interventions.
Subjects Cell Biology, Oncology
Keywords Proliferation, Colorectal cancer, Invasion, Migration, Surgery, In vitromodels,
Apoptosis
INTRODUCTION
Tumor resection combined with radio/chemotherapy is the mainstay for treatment
of colorectal cancer. However, despite expected curative surgical tumor resection,
the recurrence rate is high, and one third of the patients with colorectal cancer will
experience residual disease (Danish Colorectal Cancer Database, 2016). It is well known
that tumor resection can induce surgical stress response, and also cause the release of
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disseminated tumor cells into the circulation. Surgical stress response is characterized by
immune suppression, systemic inflammatory response, and excess reactive oxygen species
(Søndergaard & Gögenur, 2015; McMillan, Canna & McArdle, 2003; Roxburgh et al., 2009),
leading to favorable conditions for the remaining cancer cells to grow, and, consequently,
increase the risk of getting residual disease (Van der Bij et al., 2009).
The perioperative period is short but important for cancer outcome. In particular
the first months of the postoperative period are critical (Van der Bij et al., 2009). Genetic
changes of blood components occur rapidly within the first 4 to 12 h postoperatively, and
their expression levels remain high for the first days and up to several weeks after surgery
(Xiao et al., 2011). The metastatic process is complex, and includes several biological
processes such as cell detachment, expression and release of proteolytic enzymes, which are
able to degrade extracellular matrix, induce cell migration, and cell invasion into distant
organs consequently leading to distant cancer recurrence (Bird, Mangnall & Majeed, 2006).
For understanding of the process leading to cancer recurrence, it is crucial to exploring
the molecular mechanisms activated due to surgery. Previously, much focus has been
on identifying single plasma components, and exploring individual mechanisms leading
to development of metastatic disease. However, it is now well-recognized that cellular
mechanisms, by which tumor recurrence is enhanced postoperatively, are multifactorial
processes, involving several plasma molecules and a network of different mechanisms
(Xiao et al., 2011). To explore the overall effects of surgically-induced changes of plasma
proteins on postoperative tumor growth, in vitro tumor cell models can be used. Moreover,
they can be used to investigate different types of surgery, anesthetics, and preoperative
interventions. Our aim was therefore to systematically review the literature concerning
the use of in vitro models to investigate cancer cell growth and metastatic ability of serum
taken pre- and postoperatively from patients undergoing surgery for colorectal cancer.
MATERIALS AND METHODS
This systematic review was performed according to the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-analyses) guidelines (Moher et al., 2009). The
selection of papers for the study was based on the PICO principles (Moher et al., 2009).
The population (P) of interest was patients diagnosed with colon or rectal cancer. The
intervention (I) was surgery for colon or rectal cancer, both minimally invasive and
open conventional surgery. The comparison (C) was at least one blood sample taken
pre- and postoperatively. The outcome (O) was the use of serum samples to investigate
cell growth/proliferation, cell migration, cell invasion and/or cell death/apoptosis in in
vitro cell models. The detailed systematic literature search was conducted in PubMed and
EMBASE with no start date and April 2016 as the end date. The full PubMed and EMBASE
search strategy is reported in Appendix S1. No review protocol exists. For study selection,
Covidence online software (http://www.covidence.org) was used. Two reviewers (MG and
TK) independently reviewed title and abstracts for all identified studies following full text
assessment of eligible studies. From these full text citations, those that satisfied all criteria
for study inclusion were included in the review. Discrepancies were discussed and resolved
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by consensus betweenMG and TK. To identify additional studies for the systematic review,
all relevant references from identified papers were reviewed by MG and TK.
For bias assessment, the Newcastle-Ottawa quality assessment scheme, which is a
‘‘star-based’’ scoring system, was modified. The scheme was modified in accordance with
the identified bias in the three categories: selection, compatibility and outcome. In the
selection category, we specifically looked for the patient population as a true representative
of the population, if the patients have received neoadjuvant chemotherapy, if there
were differences between the treatment groups (if more than one treatment group was
explored), if blood samples were collected pre-and postoperatively, and if the study used
in vitro studies. In the compatibility category, comparison between the cohorts based on
design and analysis, e.g., if the patient cohort was homogeneous, how the in vitro data were
collected and if cancer cells were used as the in vitromodel system was investigated. In the
outcome category, the recording of the study results, were they properly recorded, and was
the follow-up long enough to detect the outcome were studied.
RESULTS
Study selection
In total, 984 abstracts, 740 abstracts from PubMed and 244 abstracts from EMBASE
were identified (Fig. 1). When 29 duplicates were excluded and title/abstracts reviewed
in the remaining 955 abstracts, 949 abstracts were excluded. The remaining six papers
were reviewed in details. Of these, five papers were included in the study (Fig. 2)
(Kumara et al., 2009; Shantha Kumara et al., 2012; Salvans et al., 2014; Xu et al., 2016;
Shantha Kumara et al., 2009). The last study was excluded as the patient group consisted
of patients undergoing surgery for either colorectal cancer or gastric bypass and was
therefore not a homogeneous group of patients undergoing surgery for colorectal cancer
(Kirman et al., 2002). No additional studies were identified after reviewing references
in the five included papers. For further analysis, we divided the studies into studies
investigating cell proliferation/cell growth, cell migration, cell invasion and apoptosis/cell
death (Tables 1 and 2). All five studies investigated cell proliferation and cell invasion,
whereas three studies investigated cell migration (Kumara et al., 2009; Shantha Kumara
et al., 2012; Salvans et al., 2014). Only one study investigated cell death/apoptosis (Xu et
al., 2016). Two studies used cancer cell lines (SW620, derived from Human Caucasian
colon adenocarcinoma; MDA-MB-231, derived from invasive ductal carcinoma and
LoVo, derived from colorectal adenomacarcinoma) in their in vitro studies (Salvans et
al., 2014; Xu et al., 2016), whereas the remaining three studies used human endothelial
vein endothelial cell (HUVEC; derived from the endothelium of veins from the umbilical
cord) (Kumara et al., 2009; Shantha Kumara et al., 2012; Shantha Kumara et al., 2009).
In two studies, minimal invasive colorectal surgery was performed (Kumara et al., 2009;
Shantha Kumara et al., 2009). Open conventional surgery was performed in the remaining
three studies (Shantha Kumara et al., 2012; Salvans et al., 2014; Xu et al., 2016). One study
investigated postoperative peritoneal infection due to anastomotic leak (Salvans et al.,
2014), one study investigated general anesthesia with gas or propofol (Xu et al., 2016), and
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Figure 1 Flow chart of study selection.
Full-size DOI: 10.7717/peerj.4033/fig-1
one study investigated preoperative intervention with GMCSF (Shantha Kumara et al.,
2009).
Risk of bias
Study bias was assessed using a modified Newcastle-Ottawa quality assessment scheme
(Higgins & Green, 2011) defined in sections of selection, compatibility and outcome. The
maximum score was 11 stars (12 if the study was a randomized trial with a control group)
and the overall assessment scores varied from 7–11 (Fig. 3). In the selection section,
patients from three studies had either received neoadjuvant chemotherapy or no statement
was given (Kumara et al., 2009; Shantha Kumara et al., 2012; Salvans et al., 2014). In the
compatibility section, colon cancer cell lines were only used in two studies (Salvans et al.,
2014; Xu et al., 2016). Two study populations consisted of two patient cohorts (Kumara et
al., 2009; Shantha Kumara et al., 2012), one study was a prospective matched cohort study
(Salvans et al., 2014) and two studies were randomized clinical studies (Xu et al., 2016;
Shantha Kumara et al., 2009). In two studies, blood samples were pooled into time-periods
of seven days (Kumara et al., 2009; Shantha Kumara et al., 2012).
Cell proliferation
Cell proliferation was measured in all five included studies, but with different assays. Cell
proliferation was measured by determination of endothelial cell branch point formation
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Figure 2 Study flow. Illustration of the study flow from blood sampling and in vitro cultures to assess-
ment of cell growth and metastatic ability. HUVEC, human umbilical vein endothelial cells.
Full-size DOI: 10.7717/peerj.4033/fig-2
of HUVECs (Kumara et al., 2009; Shantha Kumara et al., 2012; Shantha Kumara et al.,
2009), or cancer cell proliferation measured by colorimetric assays (Salvans et al., 2014;
Xu et al., 2016). Due to lack of samples at specific days, postoperative blood samples
were pooled in time-periods of seven days in two studies (Kumara et al., 2009; Shantha
Kumara et al., 2012). Compared with preoperative serum, postoperative serum stimulated
in vitro endothelial cell branch point formation two and three weeks after minimal invasive
(p= 0.0001 and p= 0.010, respectively) and open (p= 0.0001 and p= 0.0001, respectively)
surgery for colorectal tumor resection (Kumara et al., 2009; Shantha Kumara et al., 2012).
The effect was seen from postoperative day five (Shantha Kumara et al., 2009) and until
three weeks after surgery (Kumara et al., 2009; Shantha Kumara et al., 2012). Serum taken
four weeks after surgery did not significantly increase endothelial cell branch point
formation compared with the effect of preoperative serum (Kumara et al., 2009; Shantha
Kumara et al., 2012). No differences in endothelial cell branch point formation were seen
postoperatively when comparing minimal invasive and open surgery (Kumara et al., 2009;
Shantha Kumara et al., 2012). When using colorimetric assay, serum from postoperative
day one and four also significantly stimulated cancer cell proliferation compared with
serum taken preoperatively (p= 0.005 and p= 0013, respectively) (Salvans et al., 2014; Xu
et al., 2016). Taken together, all five studies showed that postoperative serum stimulated
in vitro cell proliferation from 24 h and up to three weeks after minimal invasive or open
conventional surgery for colorectal cancer.
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Table 1 Study characteristics.
First author Journal No of
patients
Intervention Comparator Cell lines
Kumara et al. (2009) Annals of surgery 105 Minimal invasive col-
orectal resection
Pre-operative vs
PODa7 and at
varying times for
up to 2 months.
Human umbilical
vein endothelial
cell (HUVEC)
Shantha Kumara et al. (2012) Surgical
endoscopy
53 Open surgery for rec-
tal (n = 25) or colon
(n= 28) cancer
Pre-operative vs
POD7-33
Human Um-
bilical Vein En-
dothelial cell
(HUVEC)
Salvans et al. (2014) Annals of Surgery 94 Colorectal cancer
surgery with (n= 47)
or without (n = 47)
infection from anas-
tomotic leak (n= 34)
or interabdominal ab-
scess (n= 13)
Pre-operative vs
POD4
Colon cancer
cell lines: WS620
(invasion assay)
Breast cancer cell
lines: MDA-MB-
231 (proliferation
and migration)
Xu et al. (2016) Anaesthesia 40 Open surgery for
colon cancer, receiving
general anesthesia with
gas (n= 20) or propo-
fol (n= 20)
Pre-operative vs
POD1
Colon cancer cell
line: LoVo
Shantha Kumara et al. (2009) EJSO 59 Minimal invasive col-
orectal resection and
intervention with
GMCSF (n = 29) or
placebo (n= 30)
Pre-operative vs
POD5
Human umbilical
vein endothelial
cell (HUVEC)
Notes.
aPOD: postoperative day.
Cell migration
Cell migration was investigated in three of the five included studies (Kumara et al.,
2009; Shantha Kumara et al., 2012; Salvans et al., 2014). Compared to serum taken
preoperatively, endothelial cell migration was significantly increased when stimulated
with serum taken two and three weeks postoperatively, irrespective of patients undergoing
minimal invasive (p= 0.001) or open conventional (p< 0.0001 and p= 0.0001 for
week 2 and 3, respectively) surgery (Kumara et al., 2009; Shantha Kumara et al., 2012).
Moreover, migration of HUVECs was significantly higher when cultured with serum
taken three weeks after open conventional surgery, compared with serum from minimal
invasive surgery (p< 0.001) (Salvans et al., 2014; Xu et al., 2016). Serum from patients
with peritoneal infection after surgery significantly increased cell migration compared with
controls (p< 0.05) (Salvans et al., 2014). Collectively, these results show that postoperative
serum taken from four days and up to three weeks after surgery, significantly stimulated in
vitro cell migration of both endothelial cells and cancer cells, and that open conventional
surgery tend to improve cell migration compared to minimal invasive surgery.
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Table 2 Outcome/results from the studies.
Author Measurement/methods Outcome/results
Cell proliferation
(vs PreOPd samples)
Cell migration
(vs PreOP samples)
Cell invasion
(vs PreOP samples)
Apoptosis
(vs PreOP samples)
Kumara et al. (2009) Cell proliferation: en-
dothelial cell branch point
formation assay
PODc7-13:
increased (p= 0.0001)
POD7-13:
increased (p= 0.001)
POD7-13:
increased (p= 0.001)
NAa
Cell migration: CBA 100
Cytoselect cell migration
assay (Cell Biolabs Inc)
POD14-20:
increased (p= 0.001)
POD14-20:
increased (p= 0.001)
POD14-20:
increased (p= 0.010)
Cell invasion: CBA 100
Cytoselect kit (Cell Biolabs
Inc)
POD21-27: unchanged POD21-27: unchanged POD21-27: unchanged
Shantha Kumara et al. (2012) Cell proliferation: en-
dothelial cell branch point
formation assay
POD7-13:
increased (p< 0.0001)
POD 7-13:
increased (p< 0.0001)
POD 7-13:
increased (p< 0.0001)
NA
Cell migration: CBA 100
Cytoselect cell migration
assay (Cell Biolabs Inc)
POD14-20:
increased (p< 0.0001)
POD14-20:
increased (p< 0.0001)
POD14-20:
increased (p< 0.0001)
Cell invasion: CBA 100
Cytoselect kit (Cell Biolabs
Inc)
POD21-33:
unchanged (p= 0.09)
POD21-33:
unchanged
POD21-33:
increased (p= 0.04)
OS vs MICS:
unchanged
OS vs MICS:
sign week 3
OS vs MICS:
sign week 2
Salvans et al. (2014) Cell proliferation: colori-
metric assay (Landegren
and Givens)
POD4 (infection):
increased (p= 0.013)
POD4 (infection):
increased (p< 0.05)
POD4 (infection):
unchanged
NA
Cell migration: Boyden
chamber assay (Corning
Life Sceinces)
Cell invasion: Boyden
chamber assay (Corning
Life Sceinces)
(continued on next page)
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Table 2 (continued)
Author Measurement/methods Outcome/results
Cell proliferation
(vs PreOPd samples)
Cell migration
(vs PreOP samples)
Cell invasion
(vs PreOP samples)
Apoptosis
(vs PreOP samples)
Xu et al. (2016) Cell proliferation: MMT
assay (Sigma)
POD1: gas vs. propofol:
reduced (p= 0.005)
NA POD1: PEA vs SGA:
reduced (p< 0.001)
Apoptosis: POD1:
gas vs. propofol:
increased (p< 0.001)
Cell invasion: Boyden
chamber assay (BD Bio-
sciences)
Cell viability/apoptosis:
ApoLive-Glo Multiplex as-
say (promega)
Shantha Kumara et al. (2009) Cell proliferation: En-
dothelial cell branch point
formation by ECM625 an-
giogenesis kit (Chemicon)
POD5 (control):
increased (p= 0.001)
NA POD5 (control):
unchanged
NA
Cell invasion: CBA 100
Cytoselect kit (Cell Biolabs
Inc.)
POD5 (GMCSF):
reduced (p=NSb)
POD5 (GMCSF):
reduced (P =NS)
Notes.
aNA: not assessed.
bNS: not significant.
cPOD: postoperative day.
dPreOP: preoperative.
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Figure 3 Bias assessment. Bias assessment using a modified Newcastle-Ottawa scale. The studies were as-
sessed on three perspectives: selection of the study groups, comparability of the groups and if the studies
met the outcome. ¤, Indicated bias item was met in the study. #: Indicated bias item was not met in the
study.
Full-size DOI: 10.7717/peerj.4033/fig-3
Cell invasion
Cell invasion, as measured by invasion of cells through a porous membrane of the
extracellular matrix, was determined in all five included studies (Kumara et al., 2009;
Shantha Kumara et al., 2012; Salvans et al., 2014; Xu et al., 2016; Shantha Kumara et al.,
2009). In two studies, postoperative blood samples were combined into seven-days’ time
periods. In these studies, cell invasion was increased up to three weeks after surgery
compared with samples taking preoperatively, regardless which surgical method was
performed (Kumara et al., 2009; Shantha Kumara et al., 2012). For patients undergoing
open tumor resection, blood samples from postoperative day 21–33 (week four) also
significantly stimulated invasion of HUVECs compared to preoperative serum samples
(p= 0.04). Moreover, invasion of HUVECs was significantly higher when cultured with
serum taken two weeks after open conventional surgery, compared with serum from
minimal invasive surgery (p= 0.036) (Salvans et al., 2014; Xu et al., 2016). Serum from
patients with peritoneal infection did not increase postoperative cell invasion (Salvans
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et al., 2014), however, serum from patients receiving anesthesia with propofol inhibited
cancer cell invasion on postoperative day one compared with general anesthesia with gas
(p= 0.004) (Xu et al., 2016). Preoperative intervention with GMCSF significantly reduced
endothelial cell invasion at postoperative day five compared with preoperative taken serum
(Shantha Kumara et al., 2009). Collectively, these results show that postoperative serum
taken from four days and up to four weeks after surgery significantly stimulated in vitro cell
invasion of endothelial cells and cancer cells regardless of the surgical method. Anesthesia
with propofol and preoperative treatment with GMCSF prevented postoperative cancer
cell invasion.
Cell viability/apoptosis
Only one study investigated cell death/apoptosis (Xu et al., 2016) and showed that the
viability of cancer cells cultured in the presence of postoperative serum taken from
patients, who had received general anesthesia with gas, was higher compared with serum
from patients receiving anesthesia with propofol (p= 0.01). Similarly, apoptosis was
increased in serum from patients receiving anesthesia with propofol compared to patients
receiving general anesthesia with gas (p< 0.001). Collectively, this shows that, compared
with general anesthesia with gas, anesthesia with propofol reduced postoperative cell
viability and increased cell death in cancer cells.
Plasma protein measurements in combination with in vitro models
In two of the included papers, plasma protein levels were determined in parallel to
the in vitro studies (Kumara et al., 2009; Shantha Kumara et al., 2009). Changes in pro-
angiogenic proteins: vascular endothelial growth factor (VEGF), Angiopeotin-1 and -2 in
serum samples collected preoperatively and during the first two postoperative months,
were determined by enzyme-linked immunosorbent assay (ELISA). Expression of VEGF
was significantly increased at postoperative day five, seven, and 13. The expression of
angiopoitin-2 was increased in all collected postoperative serum samples. No significant
changes were seen in the expression of angiopoitin-1 (Kumara et al., 2009). Compared to
preoperative taken serum, the expression of soluble Vascular Endothelial Growth Factor
Receptor 1 (sVEGFR1) was increased at postoperative day one and five in both placebo
and GMCSF-treated group (Shantha Kumara et al., 2009), but the level was higher in the
GMCSF-treated group. Angiopoitin-2 expression was increased in postoperative samples
from both groups, but more pronounced in the GMCSF-group at postoperative day
five. Expression of angiopoitin-1 was unchanged in both groups at any time point. The
level of VEGF was significantly increased in both placebo and GMCSF-treated group at
postoperative day five. None of the studies made correlations between the level of specific
perioperative plasma proteins and the results from the in vitro models.
DISCUSSION
We identified five studies using in vitromodels to compare the level of cell proliferation/cell
growth, cell migration, cell invasion and cell viability/apoptosis in serum samples taken
pre- and postoperatively. All five studies demonstrated that surgery-induced changes in
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plasma components lead to changes in cell growth andmetastatic ability of both endothelial
and cancer cells. Regardless of the surgical method and if endothelial or cancer cells were
used, postoperative in vitro cell proliferation was stimulated from 24 h and up to three
weeks after surgery, whereas in vitro cell migration and invasion were stimulated from four
days and up to three weeks after surgery. Finally, anesthesia with propofol and preoperative
treatment with GMCSF prevented postoperative cancer cell invasion.
A modified Newcastle-Ottawa scheme was used to identify bias. HUVECs have become
the standard for many cell-based assays, and in three of the five studies HUVECs were used
instead of cancer cells in the in vitro models (Kumara et al., 2009; Shantha Kumara et al.,
2012; Shantha Kumara et al., 2009). A strength in the reviewwas that similar outcomes have
beenmeasured in all five included studies. Although different cell lines were used, the results
from the in vitromodels were similar among the included studies. This confirms that in vitro
models are reliable and useful in different settings. In contrast, a limitation in the review
was that different cell lines were used and that there were variations among the studies in
the days investigated postoperatively. In three studies, blood samples were investigated at
day one, four or five postoperatively (Salvans et al., 2014; Xu et al., 2016; Shantha Kumara
et al., 2009) whereas in the remaining two studies blood samples from different days were
pooled into time-periods of seven days (Kumara et al., 2009; Shantha Kumara et al., 2012).
Although the results from the two types of blood sampling were similar, there was a
risk of losing information when blood samples from several days were pooled. In the five
included studies, the samples size was relative small, varied from 40–105 patients. However,
as all studies showed similar stimulation of postoperative in vitro cell proliferation, cell
migration and invasion, it indicates sufficient number of patients in all studies. The smallest
study, including only 40 patients (20 in each arm), showed that anesthesia with propofol
prevented postoperative cancer cell invasion (Xu et al., 2016), which is in line with the
literature showing that propofol improves long-term cancer outcome compared to the
use of general anesthesia with gas (Heaney & Buggy, 2012). Thus, the sample size seems
sufficient in all included studies, but it will be preferred if larger confirming studies will
be performed to confirm these results. The study population varied among the studies.
One study consisted of patients from a prospective matched cohort study (Salvans et al.,
2014), another was a combination of different prospective studies (Kumara et al., 2009).
One study included patients from two plasma banks (Shantha Kumara et al., 2012), and
two studies were randomized trials (Xu et al., 2016; Shantha Kumara et al., 2009). Thus, the
heterogeneity of the study design is a limitation, which could make the studies difficult to
compare. However, it is also a strength that irrespective of study designs, cell proliferation
and metastatic ability was improved post-operatively. It is also a limitation that only one
study investigated perioperative intervention and that not all studies mentioned if the
patients had received neoadjuvant chemotherapy. Finally, three of the five studies were
from the same research group (Kumara et al., 2009; Shantha Kumara et al., 2012; Shantha
Kumara et al., 2009), however, although overlapping studies in two papers (Kumara et al.,
2009; Shantha Kumara et al., 2012), only 13 patients receiving granulocyte macrophage
colony stimulating factor (GMCSF) might have been included in two studies (Kumara et
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al., 2009; Shantha Kumara et al., 2009). We have, without success, tried to get information
on these patients from the corresponding author on the paper.
Despite conflicting results regarding the reduced risk of disease recurrence among
colorectal cancer patients when usingminimal invasive surgery (Lacy et al., 2002;Kirman et
al., 2005; Schwenk et al., 2000; Belizon et al., 2006; Heaney & Buggy, 2012), it is now general
practice for most surgical procedures with the advantage of less postoperative morbidity
and less surgical trauma (Lacy et al., 2002; Veldkamp et al., 2005). Minimal invasive surgery
is associated with less postoperative changes in blood composition (Kirman et al., 2005;
Schwenk et al., 2000; Belizon et al., 2006). Lower postoperative levels of interleukin-6, C-
reactive protein and VEGF was found in serum from patients undergoing minimal invasive
surgery compared to patients undergoing open conventional surgery (Belizon et al., 2006;
Schwenk et al., 2000), and a decrease in the level of the cancer cell growth inhibitory
protein, and Insulin-like growth factor-binding protein 3 (IGFBP-3), was determined in
postoperative serum from patients undergoing open conventional surgery compared to
minimal invasive surgery (Kirman et al., 2005). In this review, serum taken postoperatively
significantly stimulated in vitro cell invasion and migration compared with serum taken
preoperatively regardless of the surgical method.
The use of anesthesia with propofol for primary cancer resection improved long-term
cancer outcome compared to the use of general anesthesia with gas (Heaney & Buggy, 2012).
Here we found that the in vitro models could be used to determine differences between
the uses of anesthetics. Postoperative cell proliferation and invasion were reduced when
colon cancer cells were treated with serum from patients, who had received anesthesia with
propofol. In contrast, serum from patients, who had received anesthesia with gas, reduced
cancer cell death/apoptosis. The differences seen in the in vitro studies likely reflect the
differences in surgery-induced release of serum components as previously shown (Xu et al.,
2014). As none of the included studies correlated the level of specific perioperative plasma
proteins with the results from the in vitro models, such investigations are warranted.
Surgically-induced stress response is a major problem resulting in increased morbidity,
mortality and delay of initiation of oncological treatment. Although the first month after
tumor resection in theory should be an ideal time for initiation of the oncological treatment,
it has traditionally been a ‘‘no-touch’’ period due to concerns of recovery (Horowitz et al.,
2015). However, it is of interest to explore the use of preoperative immunomodulation to
reduce the risk of getting surgery-induced disease recurrence, andmodels to verify the effect
of immune modulation is necessary. One of the included studies investigated the effect of
perioperative intervention with GMCSF (Shantha Kumara et al., 2009). GMCSF prevents
tumor growth in a murine carcinoma model (Hill et al., 1996), and here GMCSF reduced
postoperative in vitro cell growth and invasion (Shantha Kumara et al., 2009). Thus, based
on the included studies, in vitro models can be used as a reliable test to verify the effect
of preoperative intervention to optimize the immune system, and the use of such studies
should therefore be further investigated, preferably in combination with determination of
changes in serum components during the perioperative period.
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CONCLUSION
This systematic review has shown that in vitro models can be used to investigate the
multifunctional mechanisms activated upon surgery leading to increased cell growth and
metastatic ability both in the context of minimal invasive/open conventional surgery, use
of anesthesia, and preoperative interventions. Although we were only able to identify five
rather heterogeneous studies, we suggest that the use of in vitro studies should be further
explored as a tool to investigate the effect of intervention studies designed to improve and
reduce the length of the postoperative period before oncological treatment.
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